.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

QuintilesIMS
Queensland Health
McKinsey
McKesson
Johnson and Johnson
Express Scripts
US Department of Justice
Teva
Fuji
Merck

Generated: December 13, 2017

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR
FLUTICASONE FUROATE

« Back to Dashboard

Clinical Trial Listing

Trial ID Title Status Sponsor Phase Summary
NCT00000577 Asthma Clinical Research Network (ACRN)CompletedNational Heart, Lung, and Blood Institute (NHLBI)Phase 3 This study will establish a network of interactive asthma clinical research groups to evaluate current therapies, new therapies, and management strategies for adult asthma.
NCT00000622 Childhood Asthma Research and Education (CARE) NetworkCompletedNational Heart, Lung, and Blood Institute (NHLBI)Phase 3 The purpose of this study is to evaluate current and novel therapies and management strategies for children with asthma. The emphasis is on clinical trials that help identify optimal therapy for children with different asthma phenotypes, genotypes, and ethnic backgrounds and children at different developmental stages.
NCT00071552 Efficacy of QVAR vs Flovent Diskus on Small Airways in Poorly Controlled Asthmatic Adolescents/Adult PatientsTerminatedTeva Branded Pharmaceutical Products, R&D Inc.Phase 4 The primary objective of this study is to evaluate the effect of Beclomethasone dipropionate HFA on small airways compared to Fluticasone propionate powder for inhalation administered twice daily to poorly controlled asthmatics.
NCT00102765 Study Of Asthma In Patients Of African DescentCompletedGlaxoSmithKlinePhase 4 This study will last up to 62 weeks. You will visit the clinic up to 17 times. Certain clinic visits will include physical examination, medical history review and lung function tests. The purpose of this study is to see if one asthma drug (fluticasone propionate/salmeterol) is better in reducing the number of asthma exacerbations compared with another drug (fluticasone propionate alone)
NCT00102882 Study Of Asthma And Genetics In Patients To Be Treated With Fluticasone Propionate/Salmeterol Or Salmeterol XinafoateCompletedGlaxoSmithKlinePhase 4 This study may last up to 36-38 weeks. Patients will visit the clinic 11 times. A blood sample will be taken at Visit 1 to look at subjects' genes. Breathing tests will be done during the study. Study medicines and procedures will be provided at no cost. Patients will be treated with VENTOLIN (8 wks), ATROVENT (8 wks), then ADVAIR or SEREVENT (16 wks). ADVAIR and SEREVENT are FDA approved for the treatment of asthma in patients 4 years of age and older.
NCT00109486 Safety Study To Assess Growth In Children With Seasonal Allergic And/Or Perennial Allergic Rhinitis Treated With GW685698X Aqueous Nasal Spray Or Placebo Nasal SprayCompletedGlaxoSmithKlinePhase 3 The purpose of this study is to assess any effect in children with seasonal and/or perennial allergic rhinitis by GW685698X aqueous nasal spray (versus vehicle placebo nasal spray) on growth using knemometry.
NCT00115492 Advair® DISKUS® Versus Serevent® DISKUS® For Chronic Obstructive Pulmonary Disease ExacerbationsCompletedGlaxoSmithKlinePhase 4 This study evaluates the effect of two medicines on COPD (Chronic Obstructive Pulmonary Disease) exacerbations. This study will last up to 56 weeks, and subjects will visit the clinic 10 times. Subjects will be given breathing tests and will record their breathing symptoms daily on diary cards. All study related medicines and medical examinations will be provided at no cost. The two drugs used in this study have been approved by FDA for use in patients with COPD.
NCT00115622 Study In Adults And Adolescents With Seasonal Allergic RhinitisCompletedGlaxoSmithKlinePhase 3 The purpose of the study is to compare the efficacy and safety of an investigational nasal spray compared with placebo nasal spray in the treatment of seasonal allergic rhinitis. Allergic rhinitis is an inflammatory disorder of the upper airway that occurs following allergen exposure. The focus of this study, seasonal allergic rhinitis (SAR), is one type of allergic rhinitis that is triggered by the pollen from trees, grasses, and weeds. Commonly referred to as "hay fever", it is characterized by sneezing, nasal congestion and pruritus, rhinorrhea, and pruritic, watery, red eyes.
NCT00116402 A Pilot Study of the Mechanism of Synergism Between FP and Salmeterol in Preventing COPD ExacerbationsCompletedGlaxoSmithKlinePhase 1 The purpose of this study is to evaluate the blood and airway of subjects with mild to moderate COPD while undergoing standard treatment.
NCT00116402 A Pilot Study of the Mechanism of Synergism Between FP and Salmeterol in Preventing COPD ExacerbationsCompletedUniversity of ChicagoPhase 1 The purpose of this study is to evaluate the blood and airway of subjects with mild to moderate COPD while undergoing standard treatment.
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Conditions

Condition Name

Condition Name for fluticasone furoate
Intervention Trials
Asthma 242
Pulmonary Disease, Chronic Obstructive 78
Chronic Obstructive Pulmonary Disease 33
Seasonal Allergic Rhinitis 30
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for fluticasone furoate
Intervention Trials
Asthma 204
Pulmonary Disease, Chronic Obstructive 137
Lung Diseases 135
Rhinitis, Allergic 103
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trial Locations

Trials by Country

Trials by Country for fluticasone furoate
Location Trials
Germany 369
Australia 93
Mexico 87
Chile 75
Spain 64
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for fluticasone furoate
Location Trials
California 121
Texas 112
Florida 106
South Carolina 103
North Carolina 98
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress

Clinical Trial Phase

Clinical Trial Phase for fluticasone furoate
Clinical Trial Phase Trials
Phase 4 170
Phase 3 195
Phase 2/Phase 3 4
[disabled in preview] 221
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for fluticasone furoate
Clinical Trial Phase Trials
Completed 451
Recruiting 41
Terminated 23
[disabled in preview] 75
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors

Sponsor Name

Sponsor Name for fluticasone furoate
Sponsor Trials
GlaxoSmithKline 244
Merck Sharp & Dohme Corp. 60
Novartis Pharmaceuticals 20
[disabled in preview] 82
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for fluticasone furoate
Sponsor Trials
Industry 527
Other 207
NIH 13
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

QuintilesIMS
McKinsey
UBS
Argus Health
Dow
Federal Trade Commission
Moodys
Fish and Richardson
McKesson
Chubb

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot